{"protocolSection": {"identificationModule": {"nctId": "NCT01270464", "orgStudyIdInfo": {"id": "C38072/3081"}, "secondaryIdInfos": [{"id": "2010-023342-67", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}, "briefTitle": "A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma", "officialTitle": "A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma"}, "statusModule": {"statusVerifiedDate": "2016-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-02"}, "primaryCompletionDateStruct": {"date": "2013-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-12-29", "studyFirstSubmitQcDate": "2011-01-03", "studyFirstPostDateStruct": {"date": "2011-01-05", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-03-23", "resultsFirstSubmitQcDate": "2016-04-28", "resultsFirstPostDateStruct": {"date": "2016-06-06", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2014-05-08", "dispFirstSubmitQcDate": "2014-05-08", "dispFirstPostDateStruct": {"date": "2014-05-26", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-04-28", "lastUpdatePostDateStruct": {"date": "2016-06-06", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function in patients with eosinophilic asthma as assessed by the overall change from baseline in forced expiratory volume in 1 second (FEV1)."}, "conditionsModule": {"conditions": ["Eosinophilic Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 315, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses.", "interventionNames": ["Drug: Placebo"]}, {"label": "Reslizumab - 0.3 mg/kg", "type": "EXPERIMENTAL", "description": "0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses", "interventionNames": ["Drug: Reslizumab"]}, {"label": "Reslizumab - 3.0 mg/kg", "type": "EXPERIMENTAL", "description": "3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses.", "interventionNames": ["Drug: Reslizumab"]}], "interventions": [{"type": "DRUG", "name": "Reslizumab", "description": "3.0 mg/kg or 0.3 mg/kg doses administered intravenously (iv) by qualified site personnel once every 4 weeks, for a total of 4 doses.", "armGroupLabels": ["Reslizumab - 0.3 mg/kg", "Reslizumab - 3.0 mg/kg"], "otherNames": ["Cinquil", "humanized monoclonal antibody", "CEP-38072"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo administered by iv infusion by qualified study personnel every 4 weeks for a total of 4 doses.", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline In Forced Expiratory Volume In 1 Second (FEV1) Over 16 Weeks Using Mixed Model for Repeated Measures", "description": "FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer. The during treatment (weeks 4, 8, 12 and 16) average FEV1 was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.\n\nPositive change from baseline scores indicate improvement in asthma control.", "timeFrame": "Day 0 (baseline, pre-dose), Weeks 4, 8, 12 and 16"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Forced Vital Capacity (FVC) Over 16 Weeks Using Mixed Model for Repeated Measures", "description": "The FVC is the volume of air that can be forcibly blown out after full inspiration, measured in liters. The during treatment (weeks 4, 8, 12 and 16) average FVC was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.", "timeFrame": "Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16"}, {"measure": "Change From Baseline in Forced Expiratory Flow at 25% to 75% Forced Vital Capacity (FEF 25%-75%) Over 16 Weeks Using Mixed Model for Repeated Measures", "description": "The FEF 25%-75% is the force expiratory flow at 25% to 75% of the Forced Vital Capacity (FVC). The during treatment (weeks 4, 8, 12 and 16) average FEF 25%-75% was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.", "timeFrame": "Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16"}, {"measure": "Change From Baseline in % Predicted Expiratory Volume In 1 Second (FEV1) at Week 16 and at Endpoint", "description": "The percent predicted FEV1 is the ratio of the volume of air expired in the first second of a forced expiration to the patient's predicted FEV based on a similar population without asthma. Endpoint =week 16 or early withdrawal.", "timeFrame": "Day 1 (baseline, pre-dose), Week 16, endpoint"}, {"measure": "Change From Baseline in Asthma Control Questionnaire (ACQ) Over 16 Weeks Using Mixed Model for Repeated Measures", "description": "The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions are self-assessments; the seventh item, completed by a member of the study staff, is the result of the patient's FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A higher score is an indication of poorer asthma control. The during treatment (weeks 4, 8, 12 and 16) average ACQ was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.\n\nNegative change from baseline scores indicate improvement in asthma control.", "timeFrame": "Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16"}, {"measure": "Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) at Week 16 or at Last Observed Value", "description": "The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The questionnaire is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Patients were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (1=severe impairment, 7=no impairment). The overall AQLQ score is the mean of all 32 responses. Five of the activity questions were \"patient-specific,\" which means that each patient identified and scored 5 activities in which the patient was limited by asthma; these 5 activities were identified at the first visit and retained for all subsequent follow-up visits.\n\nPositive change from baseline scores indicate improvement in quality of life. The AQLQ score was only assessed once during the study at week 16 or at early withdrawal, i.e. last postbaseline assessment if within 3 to 5 weeks of the last dose of study drug.", "timeFrame": "Day 1 (baseline, pre-dose), Week 16 or last observed value"}, {"measure": "Change From Baseline in Asthma Symptom Utility Index (ASUI) Over 16 Weeks Using Mixed Model for Repeated Measures", "description": "The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma symptoms and side effects, weighted by patient preferences (Revicki et al 1998). ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control. The during treatment (weeks 4, 8, 12 and 16) average ASUI was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.\n\nPositive change from baseline values indicate improvement in asthma symptoms. Information was obtained from questionnaire about asthma symptoms.", "timeFrame": "Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16"}, {"measure": "Change From Baseline in Short-Acting Beta-Agonist (SABA) Use Over 16 Weeks Using Mixed Model for Repeated Measures", "description": "SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit patients were asked to recall their usage of SABA therapy within the last 3 days of the scheduled visit. If usage was confirmed, the number of puffs used was recorded. For the purpose of summaries, an average daily usage was evaluated by dividing the total number of puffs recorded over 3 days by 3.\n\nThe during treatment (weeks 4, 8, 12 and 16) average SABA use was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.\n\nNegative change from baseline scores indicate improvement in asthma control.", "timeFrame": "Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16"}, {"measure": "Change From Baseline in Blood Eosinophil Count Over 16 Weeks Using Mixed Model for Repeated Measures", "description": "Blood eosinophil counts were measured using a standard complete blood count (CBC) with differential blood test at each scheduled visit, and from all patients experiencing a serious adverse event, an adverse event leading to withdrawal, or an exacerbation of asthma symptoms. The during treatment (weeks 4, 8, 12 and 16) average eosinophil counts were estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.\n\nNegative change from baseline values correlate to reduced asthma severity.", "timeFrame": "Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16"}, {"measure": "Participants With Adverse Events", "description": "An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. The last postbaseline value for approximately 10 patients in each treatment group is the 90-day follow-up visit post end-of-treatment (approx. Week 29).", "timeFrame": "Day 1 (post-dose) to Week 29"}, {"measure": "Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Abnormal Lab Values", "description": "Data represents participants with potentially clinically significant (PCS) abnormal serum chemistry, hematology (except for eosinophil values), and urinalysis values.\n\nSignificance criteria:\n\n* Blood urea nitrogen: \\>=10.71 mmol/L\n* Creatinine: \\>=177 \u03bcmol/L\n* Uric acid: M\\>=625, F\\>=506 \u03bcmol/L\n* GGT = gamma-glutamyl transpeptidase: \\>= 3\\*upper limit of normal. Normal range is 5-49 U/L.\n* Total bilirubin: \\>=34.2 \u03bcmol/L\n* White blood cells: \\<=3.0 10\\^9/L\n* Hemoglobin: M\\<=115, F\\<=95 g/dL\n* Hematocrit: M\\<0.37, F\\<0.32 %\n* Platelets: \\>=700 10\\^9/L\n* Absolute neutrophil count: \\<=1.0 10\\^9/L\n* Urinalysis: blood, glucose, ketones and total protein: \\>=2 unit increase from baseline\n\nThe last postbaseline value for approximately 10 patients in each treatment group is the 90-day follow-up visit post end-of-treatment (approx. Week 29).", "timeFrame": "Day 2 to Week 29"}, {"measure": "Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Vital Signs Values", "description": "Data represents participants with potentially clinically significant (PCS) vital sign values.\n\nSignificance criteria\n\n* Sitting pulse - high: \\>100 and increase of \\>= 30 beats/minute\n* Sitting pulse - low: \\<50 and decrease of \\>=30 beats/minute\n* Sitting diastolic blood pressure: \\>100 and increase of \\>=12 mmHg\n* Respiration rate: \\>24 and increase of \\>=10 breaths/minute\n* Body temperature: \\<96.5\u00b0 Fahrenheit or \\<35.8\u00b0 Celsius\n\nThe last postbaseline value for approximately 10 patients in each treatment group is the 90-day follow-up visit post end-of-treatment (approx. Week 29).", "timeFrame": "Day 2 to Week 29"}, {"measure": "Shifts From Baseline to Endpoint in Electrocardiogram Findings", "description": "Participant counts in each category of shift from baseline to endpoint of ECG finding. Findings summarized as normal or abnormal.", "timeFrame": "Weeks -4 to -2 (Screening Visit), Week 16"}, {"measure": "Participants With a Positive Anti-Reslizumab Antibody Status at Baseline, Week 8, Week 16, Endpoint, and Overall", "description": "Counts of participants with a positive anti-drug antibody (ADA) response during treatment is offered for the two experimental treatment arms. Blood samples were collected for determination of ADAs before study drug infusion at baseline, visit 4 (week 8), and at visit 6 (week 16: EOT or early withdrawal) from patients in all 3 treatment groups (ie, placebo, 0.3 mg/kg reslizumab, and 3.0 mg/kg reslizumab); however, only the blood samples drawn from patients treated with either 0.3 mg/kg reslizumab or 3.0 mg/kg reslizumab were analyzed. Serum samples from patients who were treated with reslizumab were analyzed for ADA by Teva (Teva Biopharmaceuticals USA, Rockville, MD) using a validated homogeneous solution-based bridging enzyme-linked immunosorbent assay (ELISA).\n\nEndpoint =week 16 or early withdrawal.", "timeFrame": "Day 1 (pre-dose), week 8, 16 and endpoint"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* The patient is male or female, 12 through 75 years of age, with a previous diagnosis of asthma. Patients 12 through 17 years of age are excluded from participating in Argentina.\n* The patient has an ACQ score of at least 1.5.\n* The patient has airway reversibility of at least 12% to beta-agonist administration at screening.\n* The patient is currently taking fluticasone at a dosage of at least 440 \u03bcg daily (or equivalent). Patients' baseline asthma therapy regimens (including but not limited to inhaled corticosteroids, leukotriene antagonists, 5-lipoxygenase inhibitors, cromolyn) must be stable for 30 days before screening, and continue without dosage changes throughout study.\n* The patient has a blood eosinophil count of at least 400/\u03bcL.\n* Female patients must be surgically sterile, 2 years postmenopausal, or must have a negative pregnancy test \u00dfHCG at screening (serum) and baseline (urine).\n* Female patients of childbearing potential (not surgically sterile or 2 years postmenopausal), must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after the end-of-treatment visit. Acceptable methods of contraception include barrier method with spermicide, abstinence, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected).\n* Written informed consent is obtained. Patients 12 through 17 years old, where participating, need to provide assent in accordance with local standards.\n* Other inclusion criteria apply.\n\nExclusion Criteria:\n\n* The patient has a clinically meaningful comorbidity that would interfere with the study schedule or procedures, or compromise the patient's safety.\n* The patient has known hypereosinophilic syndrome (HES).\n* The patient has another confounding underlying lung disorder (eg, chronic obstructive pulmonary disease, pulmonary fibrosis, or lung cancer). The patient has other pulmonary conditions with symptoms of asthma and blood eosinophilia (eg, Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis).\n* The patient is a current smoker (ie, has smoked within the last 6 months prior to screening).\n* The patient has a history of use of systemic immunosuppressive or immunomodulating agents (anti-IgE mAb, methotrexate, cyclosporin, interferon-\u03b1, or anti-tumor necrosis factor mAb) within 6 months prior to study entry (screening).\n* The patient is currently using systemic corticosteroids (includes use of oral corticosteroids).\n* The patient has a current infection or disease that may preclude assessment of asthma.\n* The patient is expected to be poorly compliant with study drug administration, study procedures, or visits.\n* The patient has any aggravating factors that are inadequately controlled (eg, gastroesophageal reflux disease).\n* The patient has participated in any investigative drug or device study within 30 days prior to screening.\n* The patient has participated in any investigative biologics study within 90 days prior to screening.\n* The patient has previously received anti-hIL-5 monoclonal antibody (eg, mepolizumab).\n* Female patients who are pregnant, or nursing, or, if of childbearing potential and not using a medically accepted, effective method of birth control (e.g. spermicide, abstinence, IUD, or steroidal contraceptive \\[oral, transdermal, implanted, and injected\\]) are excluded from this study.\n* The patient has a current infection or disease that may preclude assessment of asthma.\n* The patient has a history of concurrent immunodeficiency (human immunodeficiency, acquired immunodeficiency syndrome, or congenital immunodeficiency). Patients in Argentina must have documented serology testing for HIV performed during screening.\n* Other exclusion criteria apply.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "maximumAge": "75 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Sponsor's Medical Expert, Senior Director - Worldwide Clinical Research, MD", "affiliation": "Cephalon", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Teva Investigational Site 12", "city": "Anaheim", "state": "California", "country": "United States", "geoPoint": {"lat": 33.83529, "lon": -117.9145}}, {"facility": "Teva Investigational Site 11", "city": "Fountain Valley", "state": "California", "country": "United States", "geoPoint": {"lat": 33.70918, "lon": -117.95367}}, {"facility": "Teva Investigational Site 43", "city": "Los Angeles", "state": "California", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Teva Investigational Site 4", "city": "Orange", "state": "California", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -117.85311}}, {"facility": "Teva Investigational Site 15", "city": "Walnut Creek", "state": "California", "country": "United States", "geoPoint": {"lat": 37.90631, "lon": -122.06496}}, {"facility": "Teva Investigational Site 2", "city": "Colorado Springs", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Teva Investigational Site 24", "city": "Largo", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.90979, "lon": -82.78842}}, {"facility": "Teva Investigational Site 27", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Teva Investigational Site 5", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Teva Investigational Site 19", "city": "Tallahassee", "state": "Florida", "country": "United States", "geoPoint": {"lat": 30.43826, "lon": -84.28073}}, {"facility": "Teva Investigational Site 17", "city": "Trinity", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.18085, "lon": -82.68177}}, {"facility": "Teva Investigational Site 18", "city": "Valrico", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.93789, "lon": -82.23644}}, {"facility": "Teva Investigational Site 6", "city": "Lilburn", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.8901, "lon": -84.14297}}, {"facility": "Teva Investigational Site 3", "city": "Savannah", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "Teva Investigational Site 7", "city": "Iowa City", "state": "Iowa", "country": "United States", "geoPoint": {"lat": 41.66113, "lon": -91.53017}}, {"facility": "Teva Investigational Site 8", "city": "Omaha", "state": "Nebraska", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "Teva Investigational Site 26", "city": "Summit", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 40.71562, "lon": -74.36468}}, {"facility": "Teva Investigational Site 20", "city": "Cincinnati", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Teva Investigational Site 1", "city": "Medford", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Teva Investigational Site 73", "city": "Lincoln", "state": "Rhode Island", "country": "United States", "geoPoint": {"lat": 41.92111, "lon": -71.435}}, {"facility": "Teva Investigational Site 9", "city": "Providence", "state": "Rhode Island", "country": "United States", "geoPoint": {"lat": 41.82399, "lon": -71.41283}}, {"facility": "Teva Investigational Site 21", "city": "Charleston", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "Teva Investigational Site 16", "city": "Fort Worth", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.72541, "lon": -97.32085}}, {"facility": "Teva Investigational Site 10", "city": "Houston", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Teva Investigational Site 14", "city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Teva Investigational Site 45", "city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Teva Investigational Site 121", "city": "Ciudad Autonoma de Buenos Aire", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Teva Investigational Site 126", "city": "Ciudad Autonoma de Buenos Aire", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Teva Investigational Site 127", "city": "Ciudad Autonoma de Buenos Aire", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Teva Investigational Site 128", "city": "Quilmes-Buenos Aires", "country": "Argentina"}, {"facility": "Teva Investigational Site 123", "city": "Rosario-Santa Fe", "country": "Argentina"}, {"facility": "Teva Investigational Site 125", "city": "Rosario", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Teva Investigational Site 120", "city": "San Miguel de Tucuman - Tucuma", "country": "Argentina"}, {"facility": "Teva Investigational Site 122", "city": "San Miguel de Tucuman - Tucuma", "country": "Argentina"}, {"facility": "Teva Investigational Site 124", "city": "San Miguel de Tucuman - Tucuma", "country": "Argentina"}, {"facility": "Teva Investigational Site 261", "city": "Bruxelles", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "Teva Investigational Site 264", "city": "Bruxelles", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "Teva Investigational Site 260", "city": "Gent", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"facility": "Teva Investigational Site 263", "city": "Li\u00e8ge", "country": "Belgium", "geoPoint": {"lat": 50.63373, "lon": 5.56749}}, {"facility": "Teva Investigational Site 146", "city": "Belo Horizonte", "country": "Brazil", "geoPoint": {"lat": -19.92083, "lon": -43.93778}}, {"facility": "Teva Investigational Site 150", "city": "Florianopolis", "country": "Brazil", "geoPoint": {"lat": -27.59667, "lon": -48.54917}}, {"facility": "Teva Investigational Site 147", "city": "Porto Alegre - RS", "country": "Brazil"}, {"facility": "Teva Investigational Site 140", "city": "Porto Alegre", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Teva Investigational Site 143", "city": "Porto Alegre", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Teva Investigational Site 144", "city": "Porto Alegre", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Teva Investigational Site 145", "city": "Porto Alegre", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Teva Investigational Site 142", "city": "Santo Andr\u00e9, S\u00e3o Paulo", "country": "Brazil"}, {"facility": "Teva Investigational Site 141", "city": "Sao Paulo", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Teva Investigational Site 103", "city": "Calgary", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "Teva Investigational Site 101", "city": "Montreal", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Teva Investigational Site 104", "city": "Newmarket", "country": "Canada", "geoPoint": {"lat": 44.05011, "lon": -79.46631}}, {"facility": "Teva Investigational Site 105", "city": "Windsor", "country": "Canada", "geoPoint": {"lat": 42.30008, "lon": -83.01654}}, {"facility": "Teva Investigational Site 184", "city": "Bogota", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Teva Investigational Site 185", "city": "Bogota", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Teva Investigational Site 181", "city": "Bogot\u00e1", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Teva Investigational Site 182", "city": "Cali", "country": "Colombia", "geoPoint": {"lat": 3.43722, "lon": -76.5225}}, {"facility": "Teva Investigational Site 180", "city": "Floridablanca", "country": "Colombia", "geoPoint": {"lat": 7.06222, "lon": -73.08644}}, {"facility": "Teva Investigational Site 183", "city": "Medellin", "country": "Colombia", "geoPoint": {"lat": 6.25184, "lon": -75.56359}}, {"facility": "Teva Investigational Site 343", "city": "Grenoble", "country": "France", "geoPoint": {"lat": 45.16667, "lon": 5.71667}}, {"facility": "Teva Investigational Site 342", "city": "Marseille", "country": "France", "geoPoint": {"lat": 43.29551, "lon": 5.38958}}, {"facility": "Teva Investigational Site 341", "city": "Montpellier", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "Teva Investigational Site 340", "city": "Nantes", "country": "France", "geoPoint": {"lat": 47.21725, "lon": -1.55336}}, {"facility": "Teva Investigational Site 344", "city": "Pessac", "country": "France", "geoPoint": {"lat": 44.81011, "lon": -0.64129}}, {"facility": "Teva Investigational Site 401", "city": "Balassagyarmat", "country": "Hungary", "geoPoint": {"lat": 48.07296, "lon": 19.29614}}, {"facility": "Teva Investigational Site 406", "city": "Edel\u00e9ny", "country": "Hungary", "geoPoint": {"lat": 48.3, "lon": 20.73333}}, {"facility": "Teva Investigational Site 400", "city": "Miskolc", "country": "Hungary", "geoPoint": {"lat": 48.1, "lon": 20.78333}}, {"facility": "Teva Investigational Site 404", "city": "Mosonmagyar\u00f3v\u00e1r", "country": "Hungary", "geoPoint": {"lat": 47.86789, "lon": 17.26994}}, {"facility": "Teva Investigational Site 403", "city": "Sopron", "country": "Hungary", "geoPoint": {"lat": 47.68501, "lon": 16.59049}}, {"facility": "Teva Investigational Site 407", "city": "Sz\u00e1zhalombatta", "country": "Hungary", "geoPoint": {"lat": 47.32579, "lon": 18.92141}}, {"facility": "Teva Investigational Site 402", "city": "Tatab\u00e1nya", "country": "Hungary", "geoPoint": {"lat": 47.58494, "lon": 18.39325}}, {"facility": "Teva Investigational Site 422", "city": "Petach Tikva", "country": "Israel", "geoPoint": {"lat": 32.08707, "lon": 34.88747}}, {"facility": "Teva Investigational Site 421", "city": "Rehovot", "country": "Israel", "geoPoint": {"lat": 31.89421, "lon": 34.81199}}, {"facility": "Teva Investigational Site 420", "city": "Tel-Aviv", "country": "Israel", "geoPoint": {"lat": 32.08088, "lon": 34.78057}}, {"facility": "Teva Investigational Site 203", "city": "Distrito Federal", "country": "Mexico", "geoPoint": {"lat": 16.59, "lon": -93.02694}}, {"facility": "Teva Investigational Site 205", "city": "Distrito Federal", "country": "Mexico", "geoPoint": {"lat": 16.59, "lon": -93.02694}}, {"facility": "Teva Investigational Site 204", "city": "Guadalajara, JAL", "country": "Mexico"}, {"facility": "Teva Investigational Site 200", "city": "Hermosillo, Sonora", "country": "Mexico"}, {"facility": "Teva Investigational Site 202", "city": "Tijuana, B.C.", "country": "Mexico"}, {"facility": "Teva Investigational Site 460", "city": "Heerlen", "country": "Netherlands", "geoPoint": {"lat": 50.88365, "lon": 5.98154}}, {"facility": "Teva Investigational Site 507", "city": "Bialystok", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Teva Investigational Site 513", "city": "Gdansk", "country": "Poland", "geoPoint": {"lat": 54.35205, "lon": 18.64637}}, {"facility": "Teva Investigational Site 512", "city": "Lodz", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Teva Investigational Site 505", "city": "Lublin", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"facility": "Teva Investigational Site 500", "city": "Ostrow Wielkopolski", "country": "Poland", "geoPoint": {"lat": 51.65501, "lon": 17.80686}}, {"facility": "Teva Investigational Site 502", "city": "Sopot", "country": "Poland", "geoPoint": {"lat": 54.4418, "lon": 18.56003}}, {"facility": "Teva Investigational Site 504", "city": "Tarnow", "country": "Poland", "geoPoint": {"lat": 50.01381, "lon": 20.98698}}, {"facility": "Teva Investigational Site 602", "city": "G\u00f6teborg", "country": "Sweden", "geoPoint": {"lat": 57.70716, "lon": 11.96679}}, {"facility": "Teva Investigational Site 600", "city": "Lund", "country": "Sweden", "geoPoint": {"lat": 55.70584, "lon": 13.19321}}, {"facility": "Teva Investigational Site 601", "city": "Malm\u00f6", "country": "Sweden", "geoPoint": {"lat": 55.60587, "lon": 13.00073}}]}, "referencesModule": {"references": [{"pmid": "27056586", "type": "DERIVED", "citation": "Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. Chest. 2016 Oct;150(4):789-798. doi: 10.1016/j.chest.2016.03.032. Epub 2016 Apr 4."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Of the 1025 patients screened at 80 centers in 12 countries (Argentina, Belgium, Brazil, Canada, Colombia, Hungary, Israel, Mexico, Netherlands, Poland, Sweden, and the US), 315 patients met entry criteria at 68 centers and were considered to be eligible for enrollment.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}, {"id": "FG001", "title": "Reslizumab - 0.3 mg/kg", "description": "0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses"}, {"id": "FG002", "title": "Reslizumab - 3.0 mg/kg", "description": "3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "105"}, {"groupId": "FG001", "numSubjects": "104"}, {"groupId": "FG002", "numSubjects": "106"}]}, {"type": "Safety Analysis Set", "achievements": [{"groupId": "FG000", "numSubjects": "105"}, {"groupId": "FG001", "numSubjects": "103"}, {"groupId": "FG002", "numSubjects": "103"}]}, {"type": "Full Analysis Set", "achievements": [{"groupId": "FG000", "numSubjects": "105"}, {"groupId": "FG001", "numSubjects": "103"}, {"groupId": "FG002", "numSubjects": "103"}]}, {"type": "Pharmacokinetic Analysis Set", "achievements": [{"groupId": "FG000", "numSubjects": "105"}, {"groupId": "FG001", "numSubjects": "103"}, {"groupId": "FG002", "numSubjects": "103"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "85"}, {"groupId": "FG001", "numSubjects": "92"}, {"groupId": "FG002", "numSubjects": "88"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "18"}]}], "dropWithdraws": [{"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "7"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "4"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Randomized population", "groups": [{"id": "BG000", "title": "Placebo", "description": "Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}, {"id": "BG001", "title": "Reslizumab - 0.3 mg/kg", "description": "0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses"}, {"id": "BG002", "title": "Reslizumab - 3.0 mg/kg", "description": "3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "105"}, {"groupId": "BG001", "value": "104"}, {"groupId": "BG002", "value": "106"}, {"groupId": "BG003", "value": "315"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "44.2", "spread": "14.89"}, {"groupId": "BG001", "value": "44.5", "spread": "14.03"}, {"groupId": "BG002", "value": "43.0", "spread": "14.41"}, {"groupId": "BG003", "value": "43.9", "spread": "14.42"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Adolescents (12-17 years)", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "15"}]}]}, {"title": "Adults (18-64 years)", "categories": [{"measurements": [{"groupId": "BG000", "value": "93"}, {"groupId": "BG001", "value": "91"}, {"groupId": "BG002", "value": "99"}, {"groupId": "BG003", "value": "283"}]}]}, {"title": "From 65-84 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "17"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "62"}, {"groupId": "BG001", "value": "59"}, {"groupId": "BG002", "value": "62"}, {"groupId": "BG003", "value": "183"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "43"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "44"}, {"groupId": "BG003", "value": "132"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "85"}, {"groupId": "BG001", "value": "80"}, {"groupId": "BG002", "value": "90"}, {"groupId": "BG003", "value": "255"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "18"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "4"}]}]}, {"title": "American Indian or Alaskan Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}]}, {"title": "Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "36"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "31"}, {"groupId": "BG003", "value": "89"}]}]}, {"title": "Non-Hispanic and Non-Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "74"}, {"groupId": "BG001", "value": "73"}, {"groupId": "BG002", "value": "75"}, {"groupId": "BG003", "value": "222"}]}]}, {"title": "Unknown", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "4"}]}]}]}, {"title": "Asthma Exacerbation Within the Last 12 Months", "description": "A stratification factor with data as reported in the case report form", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Yes", "categories": [{"measurements": [{"groupId": "BG000", "value": "57"}, {"groupId": "BG001", "value": "58"}, {"groupId": "BG002", "value": "60"}, {"groupId": "BG003", "value": "175"}]}]}, {"title": "No", "categories": [{"measurements": [{"groupId": "BG000", "value": "48"}, {"groupId": "BG001", "value": "46"}, {"groupId": "BG002", "value": "46"}, {"groupId": "BG003", "value": "140"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "77.0", "spread": "20.1"}, {"groupId": "BG001", "value": "75.9", "spread": "18.8"}, {"groupId": "BG002", "value": "75.7", "spread": "20.3"}, {"groupId": "BG003", "value": "76.2", "spread": "19.70"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "166.4", "spread": "10.93"}, {"groupId": "BG001", "value": "166.2", "spread": "12.21"}, {"groupId": "BG002", "value": "165.9", "spread": "10.24"}, {"groupId": "BG003", "value": "166.2", "spread": "11.12"}]}]}]}, {"title": "Body Mass Index", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "27.7", "spread": "6.01"}, {"groupId": "BG001", "value": "27.6", "spread": "6.68"}, {"groupId": "BG002", "value": "27.4", "spread": "6.87"}, {"groupId": "BG003", "value": "27.6", "spread": "6.51"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline In Forced Expiratory Volume In 1 Second (FEV1) Over 16 Weeks Using Mixed Model for Repeated Measures", "description": "FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer. The during treatment (weeks 4, 8, 12 and 16) average FEV1 was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.\n\nPositive change from baseline scores indicate improvement in asthma control.", "populationDescription": "Full analysis set-all patients randomly assigned to treatment and treated with at least 1 dose of study drug. Number of participants analyzed includes those who contributed at least once to the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Day 0 (baseline, pre-dose), Weeks 4, 8, 12 and 16", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab - 0.3 mg/kg", "description": "0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses"}, {"id": "OG002", "title": "Reslizumab - 3.0 mg/kg", "description": "3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "101"}, {"groupId": "OG002", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.126", "spread": "0.0549"}, {"groupId": "OG001", "value": "0.242", "spread": "0.0556"}, {"groupId": "OG002", "value": "0.286", "spread": "0.0548"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "The primary variable was analyzed using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0018", "pValueComment": "The overall treatment effect for each reslizumab dose was compared to placebo using a 2-sided t-test at the a priori significance level of 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.160", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.060", "ciUpperLimit": "0.259", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0507"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "The primary variable was analyzed using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0237", "pValueComment": "The overall treatment effect for each reslizumab dose was compared to placebo using a 2-sided t-test at the a priori significance level of 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.115", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.016", "ciUpperLimit": "0.215", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0508"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Vital Capacity (FVC) Over 16 Weeks Using Mixed Model for Repeated Measures", "description": "The FVC is the volume of air that can be forcibly blown out after full inspiration, measured in liters. The during treatment (weeks 4, 8, 12 and 16) average FVC was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.", "populationDescription": "Full analysis set. Number of participants analyzed includes those who contributed at least once to the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab - 0.3 mg/kg", "description": "0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses"}, {"id": "OG002", "title": "Reslizumab - 3.0 mg/kg", "description": "3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "101"}, {"groupId": "OG002", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.172", "spread": "0.0614"}, {"groupId": "OG001", "value": "0.220", "spread": "0.0623"}, {"groupId": "OG002", "value": "0.301", "spread": "0.0613"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "As with the primary outcome, this respiratory test outcome was analyzed using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0174", "pValueComment": "The overall treatment effect for each reslizumab dose was compared to placebo using a 2-sided t-test at the a priori significance level of 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.130", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.023", "ciUpperLimit": "0.237", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0543"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "As with the primary outcome, this respiratory test outcome was analyzed using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3731", "pValueComment": "The overall treatment effect for each reslizumab dose was compared to placebo using a 2-sided t-test at the a priori significance level of 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.048", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.058", "ciUpperLimit": "0.155", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0543"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Expiratory Flow at 25% to 75% Forced Vital Capacity (FEF 25%-75%) Over 16 Weeks Using Mixed Model for Repeated Measures", "description": "The FEF 25%-75% is the force expiratory flow at 25% to 75% of the Forced Vital Capacity (FVC). The during treatment (weeks 4, 8, 12 and 16) average FEF 25%-75% was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.", "populationDescription": "Full analysis set. Number of participants analyzed includes those who contributed at least once to the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters/second", "timeFrame": "Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab - 0.3 mg/kg", "description": "0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses"}, {"id": "OG002", "title": "Reslizumab - 3.0 mg/kg", "description": "3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "101"}, {"groupId": "OG002", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.145", "spread": "0.1342"}, {"groupId": "OG001", "value": "-0.114", "spread": "0.1361"}, {"groupId": "OG002", "value": "0.089", "spread": "0.1342"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "As with the primary outcome, this respiratory test outcome was analyzed using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0552", "pValueComment": "The overall treatment effect for each reslizumab dose was compared to placebo using a 2-sided t-test at the a priori significance level of 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.233", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.005", "ciUpperLimit": "0.472", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1212"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "As with the primary outcome, this respiratory test outcome was analyzed using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8020", "pValueComment": "The overall treatment effect for each reslizumab dose was compared to placebo using a 2-sided t-test at the a priori significance level of 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.030", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.209", "ciUpperLimit": "0.270", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1215"}]}, {"type": "SECONDARY", "title": "Change From Baseline in % Predicted Expiratory Volume In 1 Second (FEV1) at Week 16 and at Endpoint", "description": "The percent predicted FEV1 is the ratio of the volume of air expired in the first second of a forced expiration to the patient's predicted FEV based on a similar population without asthma. Endpoint =week 16 or early withdrawal.", "populationDescription": "Full analysis set of participants with assessments at stated timeframes.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of predicted FEV1", "timeFrame": "Day 1 (baseline, pre-dose), Week 16, endpoint", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab - 0.3 mg/kg", "description": "0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses"}, {"id": "OG002", "title": "Reslizumab - 3.0 mg/kg", "description": "3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "101"}, {"groupId": "OG002", "value": "102"}]}], "classes": [{"title": "Week 16 (n=84, 92, 91)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.8", "spread": "11.92"}, {"groupId": "OG001", "value": "4.9", "spread": "15.06"}, {"groupId": "OG002", "value": "7.5", "spread": "14.74"}]}]}, {"title": "Endpoint (n=103, 101, 102)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.8", "spread": "13.83"}, {"groupId": "OG001", "value": "5.5", "spread": "15.16"}, {"groupId": "OG002", "value": "6.7", "spread": "15.01"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Control Questionnaire (ACQ) Over 16 Weeks Using Mixed Model for Repeated Measures", "description": "The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions are self-assessments; the seventh item, completed by a member of the study staff, is the result of the patient's FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A higher score is an indication of poorer asthma control. The during treatment (weeks 4, 8, 12 and 16) average ACQ was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.\n\nNegative change from baseline scores indicate improvement in asthma control.", "populationDescription": "Full analysis set, including participants who contributed at least once to the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab - 0.3 mg/kg", "description": "0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses"}, {"id": "OG002", "title": "Reslizumab - 3.0 mg/kg", "description": "3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "101"}, {"groupId": "OG002", "value": "101"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.494", "spread": "0.1231"}, {"groupId": "OG001", "value": "-0.732", "spread": "0.1250"}, {"groupId": "OG002", "value": "-0.853", "spread": "0.1233"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "As with the primary outcome, this respiratory test outcome was analyzed using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0014", "pValueComment": "The overall treatment effect for each reslizumab dose was compared to placebo using a 2-sided t-test at the a priori significance level of 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.359", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.577", "ciUpperLimit": "-0.140", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1110"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "As with the primary outcome, this respiratory test outcome was analyzed using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0329", "pValueComment": "The overall treatment effect for each reslizumab dose was compared to placebo using a 2-sided t-test at the a priori significance level of 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.238", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.456", "ciUpperLimit": "-0.019", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1108"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) at Week 16 or at Last Observed Value", "description": "The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The questionnaire is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Patients were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (1=severe impairment, 7=no impairment). The overall AQLQ score is the mean of all 32 responses. Five of the activity questions were \"patient-specific,\" which means that each patient identified and scored 5 activities in which the patient was limited by asthma; these 5 activities were identified at the first visit and retained for all subsequent follow-up visits.\n\nPositive change from baseline scores indicate improvement in quality of life. The AQLQ score was only assessed once during the study at week 16 or at early withdrawal, i.e. last postbaseline assessment if within 3 to 5 weeks of the last dose of study drug.", "populationDescription": "Full analysis set of participants with assessments at stated timeframes.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Day 1 (baseline, pre-dose), Week 16 or last observed value", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab - 0.3 mg/kg", "description": "0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses"}, {"id": "OG002", "title": "Reslizumab - 3.0 mg/kg", "description": "3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "101"}, {"groupId": "OG001", "value": "96"}, {"groupId": "OG002", "value": "99"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.779", "spread": "0.1817"}, {"groupId": "OG001", "value": "1.057", "spread": "0.1881"}, {"groupId": "OG002", "value": "1.138", "spread": "0.1829"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "As with the primary outcome, this respiratory test outcome was analyzed using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0241", "pValueComment": "The overall treatment effect for each reslizumab dose was compared to placebo using a 2-sided t-test at the a priori significance level of 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.359", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.047", "ciUpperLimit": "0.670", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1582"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "As with the primary outcome, this respiratory test outcome was analyzed using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0822", "pValueComment": "The overall treatment effect for each reslizumab dose was compared to placebo using a 2-sided t-test at the a priori significance level of 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.278", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.036", "ciUpperLimit": "0.591", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1591"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Symptom Utility Index (ASUI) Over 16 Weeks Using Mixed Model for Repeated Measures", "description": "The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma symptoms and side effects, weighted by patient preferences (Revicki et al 1998). ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control. The during treatment (weeks 4, 8, 12 and 16) average ASUI was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.\n\nPositive change from baseline values indicate improvement in asthma symptoms. Information was obtained from questionnaire about asthma symptoms.", "populationDescription": "Full analysis set, including patients who contributed at least once to the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab - 0.3 mg/kg", "description": "0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses"}, {"id": "OG002", "title": "Reslizumab - 3.0 mg/kg", "description": "3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "101"}, {"groupId": "OG002", "value": "101"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.082", "spread": "0.0218"}, {"groupId": "OG001", "value": "0.132", "spread": "0.0221"}, {"groupId": "OG002", "value": "0.129", "spread": "0.0218"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "As with the primary outcome, this respiratory test outcome was analyzed using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0160", "pValueComment": "The overall treatment effect for each reslizumab dose was compared to placebo using a 2-sided t-test at the a priori significance level of 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.047", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.009", "ciUpperLimit": "0.085", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0193"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "As with the primary outcome, this respiratory test outcome was analyzed using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0094", "pValueComment": "The overall treatment effect for each reslizumab dose was compared to placebo using a 2-sided t-test at the a priori significance level of 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.051", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.012", "ciUpperLimit": "0.089", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0193"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Short-Acting Beta-Agonist (SABA) Use Over 16 Weeks Using Mixed Model for Repeated Measures", "description": "SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit patients were asked to recall their usage of SABA therapy within the last 3 days of the scheduled visit. If usage was confirmed, the number of puffs used was recorded. For the purpose of summaries, an average daily usage was evaluated by dividing the total number of puffs recorded over 3 days by 3.\n\nThe during treatment (weeks 4, 8, 12 and 16) average SABA use was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.\n\nNegative change from baseline scores indicate improvement in asthma control.", "populationDescription": "Full analysis set, including patients who contributed at least once to the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "SABA puffs per day", "timeFrame": "Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab - 0.3 mg/kg", "description": "0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses"}, {"id": "OG002", "title": "Reslizumab - 3.0 mg/kg", "description": "3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "102"}, {"groupId": "OG001", "value": "101"}, {"groupId": "OG002", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "0.28"}, {"groupId": "OG001", "value": "-1.0", "spread": "0.28"}, {"groupId": "OG002", "value": "-0.9", "spread": "0.27"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "As with the primary outcome, this respiratory test outcome was analyzed using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0151", "pValueComment": "The overall treatment effect for each reslizumab dose was compared to placebo using a 2-sided t-test at the a priori significance level of 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.624", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.126", "ciUpperLimit": "-0.121", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.2551"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "As with the primary outcome, this respiratory test outcome was analyzed using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0119", "pValueComment": "The overall treatment effect for each reslizumab dose was compared to placebo using a 2-sided t-test at the a priori significance level of 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.648", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.152", "ciUpperLimit": "-0.144", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.2559"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Blood Eosinophil Count Over 16 Weeks Using Mixed Model for Repeated Measures", "description": "Blood eosinophil counts were measured using a standard complete blood count (CBC) with differential blood test at each scheduled visit, and from all patients experiencing a serious adverse event, an adverse event leading to withdrawal, or an exacerbation of asthma symptoms. The during treatment (weeks 4, 8, 12 and 16) average eosinophil counts were estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.\n\nNegative change from baseline values correlate to reduced asthma severity.", "populationDescription": "Full analysis set, including patients who contributed at least once to the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "10^9 blood eosinophil/L", "timeFrame": "Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab - 0.3 mg/kg", "description": "0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses"}, {"id": "OG002", "title": "Reslizumab - 3.0 mg/kg", "description": "3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "101"}, {"groupId": "OG002", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.035", "spread": "0.0271"}, {"groupId": "OG001", "value": "-0.358", "spread": "0.0277"}, {"groupId": "OG002", "value": "-0.529", "spread": "0.0270"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "As with the primary outcome, this respiratory test outcome was analyzed using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0000", "pValueComment": "The overall treatment effect for each reslizumab dose was compared to placebo using a 2-sided t-test at the a priori significance level of 0.05.", "statisticalMethod": "Regression, Logistic", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.494", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.542", "ciUpperLimit": "-0.447", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0242"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "As with the primary outcome, this respiratory test outcome was analyzed using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0000", "pValueComment": "The overall treatment effect for each reslizumab dose was compared to placebo using a 2-sided t-test at the a priori significance level of 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.323", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.370", "ciUpperLimit": "-0.275", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0243"}]}, {"type": "SECONDARY", "title": "Participants With Adverse Events", "description": "An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. The last postbaseline value for approximately 10 patients in each treatment group is the 90-day follow-up visit post end-of-treatment (approx. Week 29).", "populationDescription": "Safety analysis set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Day 1 (post-dose) to Week 29", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab - 0.3 mg/kg", "description": "0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses"}, {"id": "OG002", "title": "Reslizumab - 3.0 mg/kg", "description": "3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "103"}, {"groupId": "OG002", "value": "103"}]}], "classes": [{"title": "At least 1 AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "61"}]}]}, {"title": "Severe AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "7"}]}]}, {"title": "Treatment-related AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "12"}]}]}, {"title": "Withdrawn from study due to AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "6"}]}]}, {"title": "Withdrawn due to treatment-related AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Serious AE (excluding death outcome)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "Treatment-related serious AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Abnormal Lab Values", "description": "Data represents participants with potentially clinically significant (PCS) abnormal serum chemistry, hematology (except for eosinophil values), and urinalysis values.\n\nSignificance criteria:\n\n* Blood urea nitrogen: \\>=10.71 mmol/L\n* Creatinine: \\>=177 \u03bcmol/L\n* Uric acid: M\\>=625, F\\>=506 \u03bcmol/L\n* GGT = gamma-glutamyl transpeptidase: \\>= 3\\*upper limit of normal. Normal range is 5-49 U/L.\n* Total bilirubin: \\>=34.2 \u03bcmol/L\n* White blood cells: \\<=3.0 10\\^9/L\n* Hemoglobin: M\\<=115, F\\<=95 g/dL\n* Hematocrit: M\\<0.37, F\\<0.32 %\n* Platelets: \\>=700 10\\^9/L\n* Absolute neutrophil count: \\<=1.0 10\\^9/L\n* Urinalysis: blood, glucose, ketones and total protein: \\>=2 unit increase from baseline\n\nThe last postbaseline value for approximately 10 patients in each treatment group is the 90-day follow-up visit post end-of-treatment (approx. Week 29).", "populationDescription": "Safety analysis set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Day 2 to Week 29", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab - 0.3 mg/kg", "description": "0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses"}, {"id": "OG002", "title": "Reslizumab - 3.0 mg/kg", "description": "3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "103"}, {"groupId": "OG002", "value": "103"}]}], "classes": [{"title": ">=1 PCS abnormal serum chemistry value", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Blood urea nitrogen", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Creatinine", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Uric acid", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "GGT", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Total bilirubin", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": ">=1 PCS abnormal hematology value", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "White blood cells", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Hemoglobin", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Hematocrit", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Platelets", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Absolute neutrophil count", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": ">=1 PCS abnormal urinalysis value", "categories": [{"measurements": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}, {"groupId": "OG002", "value": "18"}]}]}, {"title": "Blood in urine", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "6"}]}]}, {"title": "Glucose in urine", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "5"}]}]}, {"title": "Ketones in urine", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Total protein in urine", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}]}]}, {"type": "SECONDARY", "title": "Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Vital Signs Values", "description": "Data represents participants with potentially clinically significant (PCS) vital sign values.\n\nSignificance criteria\n\n* Sitting pulse - high: \\>100 and increase of \\>= 30 beats/minute\n* Sitting pulse - low: \\<50 and decrease of \\>=30 beats/minute\n* Sitting diastolic blood pressure: \\>100 and increase of \\>=12 mmHg\n* Respiration rate: \\>24 and increase of \\>=10 breaths/minute\n* Body temperature: \\<96.5\u00b0 Fahrenheit or \\<35.8\u00b0 Celsius\n\nThe last postbaseline value for approximately 10 patients in each treatment group is the 90-day follow-up visit post end-of-treatment (approx. Week 29).", "populationDescription": "Safety analysis set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Day 2 to Week 29", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab - 0.3 mg/kg", "description": "0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses"}, {"id": "OG002", "title": "Reslizumab - 3.0 mg/kg", "description": "3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "103"}, {"groupId": "OG002", "value": "103"}]}], "classes": [{"title": ">=1 PCS abnormal vital sign", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}]}]}, {"title": "Sitting pulse - high", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Sitting pulse - low", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Sitting diastolic blood pressure - high", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Respiration rate - high", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Body temperature - low", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "13"}, {"groupId": "OG002", "value": "13"}]}]}]}, {"type": "SECONDARY", "title": "Shifts From Baseline to Endpoint in Electrocardiogram Findings", "description": "Participant counts in each category of shift from baseline to endpoint of ECG finding. Findings summarized as normal or abnormal.", "populationDescription": "Safety analysis set of participants with both baseline and endpoint values.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Weeks -4 to -2 (Screening Visit), Week 16", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab - 0.3 mg/kg", "description": "0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses"}, {"id": "OG002", "title": "Reslizumab - 3.0 mg/kg", "description": "3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "102"}, {"groupId": "OG001", "value": "99"}, {"groupId": "OG002", "value": "101"}]}], "classes": [{"title": "Normal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "70"}, {"groupId": "OG002", "value": "63"}]}]}, {"title": "Normal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "15"}]}]}, {"title": "Abnormal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "13"}]}]}, {"title": "Abnormal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "10"}]}]}]}, {"type": "SECONDARY", "title": "Participants With a Positive Anti-Reslizumab Antibody Status at Baseline, Week 8, Week 16, Endpoint, and Overall", "description": "Counts of participants with a positive anti-drug antibody (ADA) response during treatment is offered for the two experimental treatment arms. Blood samples were collected for determination of ADAs before study drug infusion at baseline, visit 4 (week 8), and at visit 6 (week 16: EOT or early withdrawal) from patients in all 3 treatment groups (ie, placebo, 0.3 mg/kg reslizumab, and 3.0 mg/kg reslizumab); however, only the blood samples drawn from patients treated with either 0.3 mg/kg reslizumab or 3.0 mg/kg reslizumab were analyzed. Serum samples from patients who were treated with reslizumab were analyzed for ADA by Teva (Teva Biopharmaceuticals USA, Rockville, MD) using a validated homogeneous solution-based bridging enzyme-linked immunosorbent assay (ELISA).\n\nEndpoint =week 16 or early withdrawal.", "populationDescription": "Pharmacokinetic analysis set. Anti-Reslizumab antibody status was not analyzed for patients in the Placebo treatment arm.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Day 1 (pre-dose), week 8, 16 and endpoint", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab - 0.3 mg/kg", "description": "0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses"}, {"id": "OG002", "title": "Reslizumab - 3.0 mg/kg", "description": "3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "103"}, {"groupId": "OG002", "value": "103"}]}], "classes": [{"title": "Overall (n=102, 103)", "categories": [{"measurements": [{"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "11"}]}]}, {"title": "Baseline (n=99, 98)", "categories": [{"measurements": [{"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "8"}]}]}, {"title": "Week 8 (n=90, 94)", "categories": [{"measurements": [{"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "10"}]}]}, {"title": "Week 16 (n=91, 89)", "categories": [{"measurements": [{"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "5"}]}]}, {"title": "Endpoint (n=101, 102)", "categories": [{"measurements": [{"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "6"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Day 1 to Week 29. The last postbaseline value for approximately 10 patients in each treatment group is the 90-day follow-up visit post end-of-treatment (approx. Week 29). Events reported during the followup were treated as treatment-emergent.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses.", "seriousNumAffected": 1, "seriousNumAtRisk": 105, "otherNumAffected": 28, "otherNumAtRisk": 105}, {"id": "EG001", "title": "Reslizumab - 0.3 mg/kg", "description": "0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses", "seriousNumAffected": 0, "seriousNumAtRisk": 103, "otherNumAffected": 20, "otherNumAtRisk": 103}, {"id": "EG002", "title": "Reslizumab - 3.0 mg/kg", "description": "3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses.", "seriousNumAffected": 4, "seriousNumAtRisk": 103, "otherNumAffected": 28, "otherNumAtRisk": 103}], "seriousEvents": [{"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 105}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 103}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 103}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 103}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 103}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 103}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 103}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 105}, {"groupId": "EG001", "numEvents": 9, "numAffected": 6, "numAtRisk": 103}, {"groupId": "EG002", "numEvents": 6, "numAffected": 6, "numAtRisk": 103}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 6, "numAtRisk": 105}, {"groupId": "EG001", "numEvents": 9, "numAffected": 8, "numAtRisk": 103}, {"groupId": "EG002", "numEvents": 11, "numAffected": 11, "numAtRisk": 103}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 24, "numAffected": 20, "numAtRisk": 105}, {"groupId": "EG001", "numEvents": 10, "numAffected": 6, "numAtRisk": 103}, {"groupId": "EG002", "numEvents": 14, "numAffected": 14, "numAtRisk": 103}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data."}, "pointOfContact": {"title": "Director, Clinical Research", "organization": "Teva Branded Pharmaceutical Products, R&D Inc", "email": "ustevatrials@tevapharm.com", "phone": "215-591-3000"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}, {"id": "D000011657", "term": "Pulmonary Eosinophilia"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000017681", "term": "Hypereosinophilic Syndrome"}, {"id": "D000004802", "term": "Eosinophilia"}, {"id": "D000007960", "term": "Leukocyte Disorders"}, {"id": "D000006402", "term": "Hematologic Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M14511", "name": "Pulmonary Eosinophilia", "asFound": "Eosinophilic Asthma", "relevance": "HIGH"}, {"id": "M7961", "name": "Eosinophilia", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M16355", "name": "Syndrome", "relevance": "LOW"}, {"id": "M19901", "name": "Hypereosinophilic Syndrome", "relevance": "LOW"}, {"id": "M10963", "name": "Leukocyte Disorders", "relevance": "LOW"}, {"id": "M9490", "name": "Hematologic Diseases", "relevance": "LOW"}, {"id": "T2886", "name": "Hypereosinophilic Syndrome", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC15", "name": "Blood and Lymph Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000515492", "term": "Reslizumab"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M10184", "name": "Immunoglobulins", "relevance": "LOW"}, {"id": "M4225", "name": "Antibodies", "relevance": "LOW"}, {"id": "M4230", "name": "Antibodies, Monoclonal", "relevance": "LOW"}, {"id": "M287460", "name": "Reslizumab", "asFound": "Diaphragmatic breathing exercises", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}]}}, "hasResults": true}